Pliant Therapeutics
PLRX
144 hedge funds and large institutions have $1.05B invested in Pliant Therapeutics in 2023 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 54 increasing their positions, 39 reducing their positions, and 36 closing their positions.
295% more call options, than puts
Call options by funds: $7.36M | Put options by funds: $1.86M
38% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 39
2.75% more ownership
Funds ownership: 95.41% → 98.17% (+2.8%)
3% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 36
1% more funds holding
Funds holding: 143 → 144 (+1)
30% less capital invested
Capital invested by funds: $1.5B → $1.05B (-$443M)
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$74.8M |
| 2 |
BlackRock
New York
|
+$61M |
| 3 |
State Street
Boston,
Massachusetts
|
+$21.7M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$21.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$41.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$38.4M |
| 3 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$35.5M |
| 4 |
Jennison Associates
New York
|
-$27.9M |
| 5 |
VA
VR Adviser
New York
|
-$27M |
PLRX Hedge Fund Activity: Q2 2023 in Review
144 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q2 2023, worth a combined $1.05B — down 30% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new PLRX positions and 36 closed out — a net gain of 1 holder — while 54 added to existing stakes and 39 trimmed.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $74.8M. The largest seller was Avidity Partners Management, cutting an estimated $41.4M.
- 144 institutional investors held Pliant Therapeutics (PLRX) as of Q2 2023, up from 143 in Q1 2023.
- Funds reported $1.05B of Pliant Therapeutics stock for Q2 2023, down 30% quarter-over-quarter.
- 37 funds opened new Pliant Therapeutics positions in Q2 2023 and 36 closed out, a net change of +1 holder.
- The largest Pliant Therapeutics buyer in Q2 2023 was Laurion Capital Management, an estimated $74.8M added.
- The largest Pliant Therapeutics seller in Q2 2023 was Avidity Partners Management, an estimated $41.4M sold.
Based on aggregated 13F filings for Q2 2023.